title: [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
abstract: BACKGROUND
  During the last few years, improvement in prognosis of the adult acute lymphoblastic leukaemia (ALL) has been modest. The probability of leukemia-free survival is 20-40%. Philadelphia-chromosome positive (BCR-ABL positive) ALL has the worse prognosis. A single centre experience with treatment of ALL in adults is reported.
  
  
  RESULTS
  Between April 1997 and July 2000, 15 consecutive patients with de novo adult ALL (7 T-lineage ALL, 7 B-lineage ALL, 1 null ALL) begin their treatment with the seven-drug induction regimen (in phase I, daunorubicin, vincristine, L-asparaginase, i.v., and prednisone, p.o.; in phase II, 6-mercaptopurine, p.o., cytosine arabinoside and cyclophosphamide, i.v.) and central nervous system (CNS) prophylaxis (methotrexate and CNS irradiation in patients without total body irradiation in conditioning regimen), with intensive consolidation (three times high-dose methotrexate and high-dose-cytarabine, i.v.), and with/out autologous peripheral blood stem cell transplantation (PBSCT) followed by maintenance chemotherapy (6-mercaptopurine and methotrexate, p.o.). Seven patients received autologous PBSCT. Median patient age was 30 years. Three patients were BCR-ABL positive at diagnosis. With median follow-up 14 month (range 0.1-46 month), seven (4 T-lineage ALL, 2 B-lineage ALL, 1 null ALL) out of 15 patients are alive in remission (four of them receiving autologous PBSCT). Causes of death were relapse (n = 3), chemotherapy related toxicity (n = 2), infection (n = 1), and acute myeloid leukaemia developed 10 months after autologous PBSCT (n = 1). All BCR-ABL positive patients died.
  
  
  CONCLUSIONS
  Chemotherapy alone and autologous PBSCT with maintenance therapy may be curative for adult patients with ALL. We can recommend these treatment options for patients without risk factors in particular.
authors.affiliation: Interní hematoonkologická klinika LF MU a FN, Brno. mdoubek@fnbrno.cz
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: Z
authors.initials: Z
authors.lastname: Korístek
authors.forename: M
authors.initials: M
authors.lastname: Protivánková
authors.forename: Y
authors.initials: Y
authors.lastname: Brychtová
authors.forename: A
authors.initials: A
authors.lastname: Oborilová
authors.forename: Z
authors.initials: Z
authors.lastname: Král
authors.forename: M
authors.initials: M
authors.lastname: Klabusay
authors.forename: M
authors.initials: M
authors.lastname: Tomíska
authors.forename: I
authors.initials: I
authors.lastname: Buchtová
authors.forename: J
authors.initials: J
authors.lastname: Vorlícek
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D015996:Survival Rate
vernacular_title: Terapie akutní lymfoblastické leukémie dospĕlých kombinací sedmi chemoterapeutik v indukcní lécbĕ, intenzivní konzolidací s autologní transplantací kmenových bunĕk krvetvorby nebo bez ní a s následnou udrzovací lécbou. Zkusenosti jednoho centra.